1 August 17, 2018 Subject: Capital Increase for Offering for Sale to Specific Investors (Private Placement), Connected Transaction, Amendments to Articles of Association/Objectives of the Company and Determination of the Date of Extraordinary General Meeting of Shareholders No. 1/2018 To: President The Stock Exchange of Thailand Enclosures: 1. Information Memorandum on the Offering of Newly Issued Ordinary Shares to Specific Investors (Private Placement) at the Offering Price with a Discount of...
( ) 5 ( ) P a g e 3 | ( ) KTFFE86 86 Krung Thai Fixed Income FIF Enhanced86 Not for Retail Investors . . . . . . . . . “ ” “ buy & hold” “ CIS ” (collective investment scheme) property infra private
Company is aware of such risks and determined the policy that focused on the procurement and management of raw material (CPO) and biodiesel’s stocks by trying to maintain inventories turnover rate between
Eng_MD&A Final Q3'19 November 13, 2019 Ref: SET-2019-011 Re: Management Discussion and Analysis for Quarter 3’ 2019 Attn. to: President The Stock Exchange of Thailand Filter Vision Public Company
www.bangkokchainhospital.com 1 บริษทั บางกอก เชน ฮอสปิทอล จ ากดั (มหาชน) Bangkok Chain Hospital Public Company Limited No. BCH.028/2020 24 February 2020 Subject : Management Discussion and Analysis for the year ended 31
August 14, 2019 Ref: SET-2019-010 Re: Management Discussion and Analysis for Quarter 2’ 2019 Attn. to: President The Stock Exchange of Thailand Filter Vision Public Company Limited and its
Group has managed its costs, internal resources, business operation and the cash flow to the maximized performance under the COVID-19 situation. The management and business operation under the COVID-19
from diminution in value of inventories amounting of 14.00 million Baht. However, the Company determined the policy that focused on the management of raw material (CPO) by trying to maintain inventories
13,118 13,155 -1.6 % 0.3 % (Gain) loss on disposals of PPE 14 -8 76 428 % -1,020 % Management benefit expense -40 -29 -31 -23 % 7.4 % Other financial cost -4 -5 -4 5.9 % -17 % EBITDA 22,404 22,884 22,636